Risk factors for aortic valve calcification in patients on regular hemodialysis

International Journal of Artificial Organs

Volumn 32, Issue 3, 2009, Pages 173-179

  Petrović, Dejan ^a   Obrenovic, Radmila ^b   Stojimirović, Biljana ^b  

^a University Clinical Center Kragujevac   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Aortic valve calcification; Ca x PO4 product; Hemodialysis; Hyperphosphatemia

Indexed keywords

BIOMINERALIZATION; BLOOD VESSELS; BODY FLUIDS; BONE; CHOLESTEROL; ECHOCARDIOGRAPHY; FACTOR ANALYSIS; HEMODIALYZERS; LIPOPROTEINS; PATIENT MONITORING; PATIENT TREATMENT; REGRESSION ANALYSIS; RISK ASSESSMENT;

AORTIC VALVE CALCIFICATION; AORTIC VALVES; CA X PO4 PRODUCT; HAEMODIALYSIS; HYPERPHOSPHATEMIA; LOGISTIC REGRESSION ANALYSIS; MULTIVARIATE LOGISTIC REGRESSIONS; RISK FACTORS; UNIVARIATE; VALVE CALCIFICATION;

DIALYSIS;

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CALCIUM; CALCIUM PHOSPHOTUS PRODUCT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALBUMIN BLOOD LEVEL; AORTA VALVE CALCIFICATION; ARTERY CALCIFICATION; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; ECHOCARDIOGRAPHY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67650699332     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200308     Document Type: Article

References (25)

1. London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the Aortic Valve in the Dialyzed Patient. J Am Soc Nephrol 2000; 11: 778-83.
2. London GM, Guerin AP, Marchais SJ. Hemodynamic Overload in End-Stage Renal Disease Patients. Semin Dial 1999; 12: 77-83.
3. Rigatto C, Parfrey PS. Uremic Cardiomyopathy: an Overload Cardiomyopathy. J Clin Basic Cardiol 2001; 4: 93-5.
4. Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant 2002; 17 (Suppl 11): S16-9.
5. Ventura JE, Tavella N, Romero C, Petraglia A, Baez A, Munoz L. Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance hemodialysis. Nephrol Dial Transplant 2002; 17: 1795-801.
6. Parfrey PS, Collingwood P, Foley RN, Bahrle A. Left ventricular disorders detected by M-meode echocardiography in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1328-31.
7. Ehrlich JE, Rumberger JA. Detection and Clinical Management of Cardiovascular Calcification in ESRD: A Review. Dial Transplant 2004; 33: 306-15.
8. Sonician M, Parissis JT. Cardiovascular Diseases and Hemodialysis: Novel Strategies for Diagnosis, Prevention and Treatment. Hellenic J Cardiol 2003; 44: 206-17.
9. Massy ZA, Kasiske BL. Prevention of cardiovascular complications in chronic renal disease. In: Loscalzo J, London GM (eds). Cardiovascular Disease in End-stage Renal Failure. New York: Oxford University Press; 2000. p 463-81.
10. Dikow R, Adamczak M, Henriquez DE, Ritz E. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int 2002; 61 (Suppl 80): S5-10.
11. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18 (Suppl 3): S2-8.
12. Bowry SK, Kuchinke-Kiehn U, Ronco C. The Cardiovascular Burden of the Dialysis Patient: The Impact of Dialysis Technology. In: Cardiovascular Disorders in Hemodialysis. Ronco C, Brendolan A, Levin NW (eds). Contrib Nephrol 2005; 149: 230-9.
13. Seibert E, Kuhlmann MK, Levin NW. Modifiable Risk Factors for Cardiovascular Disease in CKD Patients. In: Cardiovascular Disorders in Hemodialysis. Ronco C, Brendolan A, Levin NW (eds). Contrib Nephrol 2005; 149: 219-29.
14. Finn WF. Phosphorus Management in End-Stage Renal Disease. Semin Dial 2005; 18: 8-12.
15. Llach F. Cardiac Calcification: Dealing with Another Risk Factor in Patients with Kidney Failure. Semin Dial 1999; 12: 293-5.
16. Ribeiro S, Ramos A, Brandao A, Guerra A, Resina C, Vila-Lobos A, et al. Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037-40.
17. Locatelli F, Bommer J, London GM, Martin-Malo A, Wanner C, Yaqoob M, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-68.
18. Qunibi WY. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 2004; 66 (Suppl 90): S8-12.
19. Hörl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19 (Suppl 5): S2-8.
20. Goodman WG. The Consequences of Uncontrolled Secondary Hyperparathyroidism and Its Treatment in Chronic Kidney Disease. Semin Dial 2004; 17: 209-16.
21. Rufino M, Garcia S, Jimenez A, Alvarez A, Miquel R, Delgado P, et al. Heart valve calcification and calcium × phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention. Kidney Int 2003; 63 (Suppl 85): S115-8.
22. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15 (Suppl 5): S58-68.
23. 4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. J Am Soc Nephrol 2001; 12: 2131-8.
24. Nolan CR. Strategies for Improving Long-Term Survival in Patients with ESRD. J Am Soc Nephrol 2005; 16 (11 Suppl 2): S120-7.
25. Reichel H. Current treatment options in secondary renal hyperparathyroidism. Nephrol Dial Transplant 2006; 21: 23-8.